Considering the preliminary efficacy seen in the phase 1 dose escalation and the changing treatment landscape of EGFR-mutated NSCLC, the decision was made to not proceed to the randomized dose expansion of this combination. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.